SCHEMBL4295195

SCHEMBL4295195

COC(=O)c1ccc(C(=O)Nc2nccs2)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.76
NPC1 O15118 7/20 0.76
SMN1; SMN2 Q16637 4/20 0.73
LMNA P02545 2/20 0.68
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
RECQL P46063 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
HSD17B10 Q99714 2/20 0.68
AGER Q15109 1/20 0.68
MAPK1 P28482 1/20 0.67
SCD O00767 1/20 0.65
ADORA2A P29274 5/20 0.63
MAPT P10636 3/20 0.62
KDM4E B2RXH2 1/20 0.62
BRD4 O60885 1/20 0.60
CYP2C19 P33261 1/20 0.60
POLB P06746 2/20 0.59
ESR2 Q92731 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28478360 0.87 RAB9A (1.00) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL3223685 0.84 RAB9A (1.00) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL2753283 0.83 RAB9A (0.92) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL4290771 0.83 NPC1 (0.79) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL4287847 0.82 AGER (0.76) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL16378731 0.82 RAB9A (0.73) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL2307971 0.81 RAB9A (0.72) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL3200814 0.81 NPC1 (1.00) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL28801036 0.81 NPC1 (0.72) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL4293350 0.81 RAB9A (0.77) RAB9ANPC1SMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885SMN1; SMN2 1617/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885SMN1; SMN2 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.